• Explore /
  • Poster
  • / Preliminary results of a phase I trial of FT516, an off-the-shelf natural killer (NK) cell therapy derived from a clonal master induced pluripotent stem cell (iPSC) line expressing high‑affinity, non-cleavable CD16 (hnCD16), in patients (pts) with relapsed/refractory (R/R) B-cell lymphoma (BCL).

Preliminary results of a phase I trial of FT516, an off-the-shelf natural killer (NK) cell therapy derived from a clonal master induced pluripotent stem cell (iPSC) line expressing high‑affinity, non-cleavable CD16 (hnCD16), in patients (pts) with relapsed/refractory (R/R) B-cell lymphoma (BCL).

Abstract Video & Slides Poster

Authors

null

Paolo Strati

The University of Texas MD Anderson Cancer Center, Department of Lymphoma/Myeloma, Houston, TX

Paolo Strati , Veronika Bachanova , Aaron Goodman , John M. Pagel , Januario E. Castro , Kelly Griffis , Marlisa Anderson , Siminder K. Atwal , Cara Bickers , Daniel Fremgen , Christina Ly , Sarah A. Cooley , Rebecca L. Elstrom , Krish Patel

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Non-Hodgkin Lymphoma

Clinical Trial Registration Number

NCT04023071

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 7541)

DOI

10.1200/JCO.2021.39.15_suppl.7541

Abstract #

7541

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Rosa Nadal

First Author: Carlos A. Gomez-Roca

First Author: Ian W. Flinn

First Author: Rosa Nadal